Olaparib In Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Invasive Breast Cancer|Somatic Mutation Breast Cancer (BRCA1)|Somatic Mutation Breast Cancer (BRCA2)|CHEK2 Gene Mutation|ATM Gene Mutation|PALB2 Gene Mutation|RAD51 Gene Mutation|BRIP1 Gene Mutation|NBN Gene Mutation
Interventions: DRUG: Olaparib
Sponsor: Beth Israel Deaconess Medical Center
Collaborators: Johns Hopkins University|AstraZeneca|Dana-Farber Cancer Institute